Vivos Therapeutics Confirms Compliance with Nasdaq Listing Rules
Vivos Therapeutics (VVOS) has announced that it received official confirmation from Nasdaq regarding its compliance with listing requirements. Specifically, the company has met the mandate to maintain stockholders' equity of at least $2.5 million. The announcement provides regulatory clarity for the biotechnology firm following previous concerns regarding its ability to meet minimum equity thresholds. This compliance status mitigates the immediate risk of delisting from the Nasdaq exchange.
Topics: compliance Nasdaq listing rules stockholders equity
Read the full article at Seeking Alpha
Part of the story Celularity Regains Compliance with Nasdaq Listing Requirements (2 articles)